![Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.aaf6219/asset/c92e21f9-c409-4d11-bfc7-3956d7aa8ef8/assets/graphic/8-346ra92-f1.jpeg)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine
![Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline | JCO Global Oncology Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline | JCO Global Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jgo/2019/jgo.2019.5/jgo.18.00214/20190326/images/large/jgo.18.00214t4.jpeg)
Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline | JCO Global Oncology
![NEJM on Twitter: "DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 https://t.co/gvHMnGWbyE" / Twitter NEJM on Twitter: "DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 https://t.co/gvHMnGWbyE" / Twitter](https://pbs.twimg.com/media/FUaDbRIVUAAo-iP.jpg)